FDA Drug Recalls

Recalls / Class II

Class IID-1232-2020

Product

Gabapentin Capsules, USP 100mg 1,000-count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810, NDC 65862-198-99

Brand name
Gabapentin
Generic name
Gabapentin
Active ingredient
Gabapentin
Route
Oral
NDCs
65862-198, 65862-199, 65862-200
FDA application
ANDA078787
Affected lot / code info
Lot #: 198180048A, Exp. Date 04/2021; 198180061A, Exp. Date 06/2020; 19819017A1, Exp. Date 02/2021

Why it was recalled

CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed

Recalling firm

Firm
Aurobindo Pharma USA Inc.
Manufacturer
Aurobindo Pharma Limited
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
279 Princeton Hightstown Rd, East Windsor, New Jersey 08520-1401

Distribution

Quantity
26625 units
Distribution pattern
Nationwide within the United States

Timeline

Recall initiated
2020-03-18
FDA classified
2020-04-13
Posted by FDA
2020-04-22
Terminated
2024-03-25
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1232-2020. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Gabapentin · FDA Drug Recalls